Innova Captab Ltd
Innova Captab Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #12 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
4 of 4 strong
The short version
Innova Captab expects to deliver over 20% volume growth year-on-year, maintaining this growth trajectory in upcoming quarters. The company expects to maintain 20%+ volume growth in the coming periods, with an overall sales growth target of 20%+ for FY27.
From Innova Captab Ltd's Q1 FY27 earnings-call transcript · updated 9 Sept 2026.
Revenue & Sales Performance
- Innova Captab expects to deliver over 20% volume growth year-on-year, maintaining this growth trajectory in upcoming quarters.
- The guidance is approximately 20%+ volume growth for the full fiscal year FY27.
- Growth is driven by ramp-up at the Jammu plant, expanding product portfolio, onboarding new customers and geographies, and deeper engagement with existing customers.
- The Jammu facility, currently at 25-30% utilization, is projected to ramp up steadily, aiming to cross INR1,000 crores revenue.
- The company aims for 20%+ sales growth, combining volume growth and favorable pricing/product mix.
2 more points from Innova Captab Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Innova Captab Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Annual Capex Guidance for FY27 and FY28:
- Maintenance capex: INR 20-25 crores annually.
- Growth capex (existing capability augmentation/de-bottlenecking): INR 20-30 crores annually.
- Nature of Growth Capex:
- Mainly focused on internal debottlenecking, equipment replacement, and capacity doubling within existing plants.
- Greenfield/Big Expansion Projects:
- Any future large greenfield or new category expansion will be communicated to the market.
- Current large capex like Jammu (around INR 500 crores) already done; future expansions expected to be in smaller tranches (~INR 200-250 crores).
- Baddi Plant Capex Update:
- New plot acquisition done; plans are in progress and will be firmed up before public disclosure.
2 more points from Innova Captab Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Innova Captab Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Innova Captab Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹448 Cr, net profit ₹38 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Innova Captab Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Innova Captab Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Innova Captab Ltd Q1 FY27 results?
Innova Captab expects to deliver over 20% volume growth year-on-year, maintaining this growth trajectory in upcoming quarters. The company expects to maintain 20%+ volume growth in the coming periods, with an overall sales growth target of 20%+ for FY27.
What is Innova Captab Ltd share price analysis?
Innova Captab Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 43.7 with a market cap of ₹6,726 Cr. Investors should review the full earnings analysis for detailed insights.
Is Innova Captab Ltd planning capital expenditure?
Annual Capex Guidance for FY27 and FY28: - Maintenance capex: INR 20-25 crores annually.
Keep Innova Captab Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.